Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - etravirine, quantity: 200 mg - tablet - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; hypromellose; magnesium stearate - etravirine, in combination with other antiretroviral agents is indicated for the treatment of hiv-1 infection in antiretroviral treatment-experienced adults who have evidence of viral replication and resistance to non-nucleoside transcriptase inhibitors and other antiretroviral agents.,this indication is based on 24-week analyses from 2 randomised, double-blind, placebo controlled trials of etravirine. both studies were conducted in clinically advanced, 3-class antiretroviral (nnrti, n(t)rti, pi) treatment-experienced adults (see section 5.1 pharmacodynamic properties ? clinical trials).,treatment history of patients and genotypic testing should be performed to guide the use of etravirine.

Úc - Tiếng Anh - Department of Health (Therapeutic Goods Administration)

link medical products pty ltd t/a link pharmaceuticals - foscarnet sodium, quantity: 24 mg/ml - injection, solution - excipient ingredients: water for injections; hydrochloric acid - treatment of cytomegalovirus (cmv) retinitis in patients with the acquired immunodeficiency syndrome (aids). indications as at 11 november 1994: for treatment of cytomegalovirus (cmv) retinitis in patients with acquired immunodeficiency syndrome (aids); and treatment of aciclovir resistant herpes simplex virus (hsv) infections (defined by clinical trial or in-vitro resistance) in immunocompromised patients with human immunodeficiency virus (hiv) infection. note: the indication for treatment of aciclovir resistant hsv infections in immunocompromised patients with hiv infections is based primarily on the results of one open label comparative study. this was of patients with hiv infections and herpetic lesions unresponsive to aciclovir administered intravenously for 10 days or more and in-vitro documented resistance to aciclovir. eight patients were randomised to foscarnet (40mg/kg iv given eight hourly) and 6 were randomised to vidarabine 15mg/kg iv daily. the results showed a significant difference in favour o

Israel - Tiếng Anh - Ministry of Health

padagis israel agencies ltd, israel - estriol - cream - estriol 0.1 % - estriol - for the treatment of vulvo-vaginal complaints related to estrogen deficiency.

Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 100 mcg/hour - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 12.5 mcg/hour - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 25 mcg/hour - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 50 mcg/hour - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Israel - Tiếng Anh - Ministry of Health

rafa laboratories ltd - fentanyl - patches - fentanyl 75 mcg/hour - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Israel - Tiếng Anh - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

Israel - Tiếng Anh - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - coated tablets - sirolimus 1 mg - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.